Crossref
Exam 1: Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study
Clinical Gastroenterology and Hepatology · 2026-10 · 24 (10) · e9-e10
DOI: 10.1016/j.cgh.2026.07.025 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Gastroenterology and Hepatology, 2026-10.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Zitieren
APA
(2026). Exam 1: Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study. Clinical Gastroenterology and Hepatology, 24(10), e9-e10. https://doi.org/10.1016/j.cgh.2026.07.025
Vancouver
Exam 1: Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study. Clinical Gastroenterology and Hepatology. 2026;24(10):e9-e10. doi:10.1016/j.cgh.2026.07.025
BibTeX
@article{euvimed2026,
title = {Exam 1: Validation of Texas Hepatocellular Carcinoma Consortium Risk Index in the Hepatocellular Carcinoma Early Detection Strategy Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2026},
volume = {24},
number = {10},
pages = {e9--e10},
doi = {10.1016/j.cgh.2026.07.025}
}
EUVIMED